HeartWare pump approval appears likely, share price up; CoreMedix hit with trading non-compliance notice;

@FierceMedDev: BioMérieux Q1 2012 sales soar, propelled by China, India. Story | Follow @FierceMedDev

> The Nasdaq halted trading of shares of HeartWare International ($HTWR), after indications that the FDA would likely approve the company's implantable heart pump boosted the shares nearly 7%. Story

> CorMedix, ($CRMD) a medical device and pharmaceutical company developing treatments for cardiac and renal dysfunction, has received notice of delisting from NYSE Amex for non-compliance of listing standards. Release

> Toshiba's medical systems division gained FDA clearance for new dose reduction software. Release

> BioLineRx ($BLRX) gained a U.S. patent extension through at least 2029 for a medical device designed to prevent cardiac remodeling after an acute heart attack. The device is out-licensed for development to Ikaria. Release

> Smiths Medical has gained 510(k) clearance in the U.S. to market its new ViaValve Safety IV catheter. Story

Biotech News

@FierceBiotech: The Biggest R&D Spenders In Biopharma. Special Report | Follow @FierceBiotech

@JohnCFierce: AVI's retake on IIb DMD data looks to me like a second attempt at a good first impression. Release | Follow @JohnCFierce

@RyanMFierce: Perakslis: FDA plans to open up some of the FDA's liver tox data on >2000 drugs to outside parties. A good example of data sharing. | Follow @RyanMFierce

> Targacept slashes staff by half in wake of PhIII disaster. News

> The Biggest R&D Spenders in Biopharma. Report

> Scrambling to add new drugs, Big Pharma is paying big premiums for biotechs. Item

> Oregano attacks prostate cancer cells in lab experiment. Article

> Sanofi's Lemtrada beats Rebif in head-to-head MS showdown. Report

> Advocacy groups launch new services to match patients and trials. Story

Pharma News

@FiercePharma: Zyprexa sales fell off a (patent) cliff , but Lilly still beat analyst forecasts for Q1--Reuters. News | Follow @FiercePharma

> GSK scrapes up 2% sales growth despite politics, generics. Article

> Novartis strikes back at production woes with new management. Item

> Spurned GSK chief: We're the 'compelling owner' for HGS. Story

> Amgen joins Big Pharma's branded generics club with $700M deal. News

> Hungry for new drugs, pharma pays big for biotech. Story

Drug Delivery News

@DamianFierce: Tamarisk plans to "turn the industry upside down" with oral insulin platform. News | Follow @DamianFierce

> 'Chemo bomb' nanotechnology effective in halting tumors. Story

> SkyePharma's inhaler takes step toward EMA approval. Article

> Scottish scientists take a page from sci-fi with sonic screwdriver. More

> Australia jumps into life sciences fray with R&D tax credit. Piece

Biomarkers News

> Autism Awareness Month and autism biomarkers. Commentary

> Novo Nordisk, Oxford University seeking inflammation markers. More

> Urine biomarker test for autism on the horizon? Story

> 'Landmark' study splits breast cancer into 10 types. News

And Finally... Medtronic ($MDT) cracked Corporate Responsibility Magazine's top 50 list of America's best corporate citizens. Release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.